Core Insights - ARS Pharmaceuticals will present significant real-world data on the effectiveness of neffy® (epinephrine nasal spray) at the 2025 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology, showcasing its impact on treating anaphylaxis [1][2] Group 1: Presentation Details - One late-breaking oral presentation titled "Real World Data on the Effectiveness of Epinephrine Nasal Spray in Clinical Practice – Update" will be delivered on November 8, 2025 [3] - Six poster presentations will cover various aspects of neffy, including its effectiveness compared to autoinjectors, patient surveys, and case reports from clinical settings [5][6] Group 2: Expert Opinions - Dr. Jonathan Spergel emphasized that the real-world data supports intranasal epinephrine as a reliable alternative to injections, providing confidence to clinicians and patients [2] - Sarina Tanimoto, Co-founder and Chief Medical Officer of ARS Pharma, highlighted the breadth of research reinforcing the value of neffy in allergic emergencies [2] Group 3: Product Information - Neffy is indicated for emergency treatment of type I allergic reactions, including anaphylaxis, in patients aged 4 years and older who weigh at least 33 lbs [8] - The product aims to address limitations associated with traditional epinephrine auto-injectors, such as needle fear and portability issues [17]

$7.8 million in total neffy U.S. net product revenue in first quarter of 2025 neffy 1 mg available nationwide for children aged four and older and co-promotion agreement with ALK- Abelló Inc. increases neffy promotional reach to nearly 20,000 healthcare providers, including key pediatricians More than 5,000 physicians have prescribed neffy to date, reinforcing the demand for a safe, effective, needle- free treatment for severe allergic reactions including anaphylaxis Conference call to be held today, May 14 ...